Selective targeting of the tumor cell mitochondrion is a viable approach for the development of anti-cancer agents because the organelle is functionally different from that in normal cells. We recently developed a novel aryl-urea fatty acid (1; 16({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)hexadecanoic acid) that disrupted the mitochondrion and activated apoptosis in MDA-MB-231 breast cancer cells. However, currently there is little information on the structural requirements for activity of 1 analogues.
INTRODUCTION
Agents that kill cancer cells by novel mechanisms are required to develop new anti-cancer therapeutics and to induce further remissions in cancer patients who are resistant to established agents. The tumor cell mitochondrion is functionally distinct from mitochondria in normal cells and is a promising target for anti-cancer drug development because it regulates both apoptotic cell death and the synthesis of macromolecules that are required for the rapid proliferation of tumor cells. [1] Polyunsaturated fatty acids (PUFAs) are metabolised in cells to diverse lipid mediators, including prostaglandins, leukotrienes and epoxides, and secondary biotransformation products, that are important modulators of homeostasis. [2] While cytochrome P450 (CYP)
enzymes have been most widely studied for their roles in the biotransformation of drugs, natural products and other xenobiotics, [3] [4] [5] [6] several are also active in PUFA oxidation. CYPderived epoxyeicosatrienoic acids (or EETs) are formed from the ω-6 PUFA arachidonic acid and promote tumorigenesis, [7] while a number of their ω-3 PUFA-derived counterparts are antitumorigenic. [8, 9] Thus, we found that ω-3-17,18-epoxyeicosapentaenoic acid and its fullysaturated analogue impaired cell viability by decreasing proliferation and activating apoptosis. [8, 10] Others have reported that docosahexaenoic acid epoxides prevent tumor progression. [9] However, unless coadministered with epoxide hydrolase inhibitors, the instability of ω-3 epoxides in vivo, due to rapid deactivation by soluble epoxide hydrolase, prevents their use as anti-cancer agents. [9, 11] Replacement of the epoxide moiety with urea has been used to generate mimetics of ω-3 [12] and ω-6 [13, 14] epoxides. We recently reported the development of a ω-terminal aryl-urea analogue of ω-3-17,18-epoxyeicosatetraenoic acid (termed 1; see Scheme 1 for structure) that targeted the mitochondrion in MDA-MB-231 breast cancer cells to activate apoptotic cell death. [15] 4 1 is a new lead compound with promising anti-cancer activity, but we are yet to determine which pharmacophoric groups in its structure are essential for activity. The present study was designed to investigate the importance of the carboxylic acid functionality on anti-cancer activity in human MDA-MB-231 cells by preparing 1 analogues in which the carboxylate group was replaced with non-bioisosteric amide functionalities (1-A and 1-MA; Scheme 1).
We also prepared 1 analogues containing carboxylate bioisosteres from different structural classes. Thus, the hydroxamic acid (1-HA; Scheme 1), the planar heterocyclic oxo-thiadiazole
(1-OT) and the non-planar sulfur-derived sulfonate (1-SA; Scheme 2) isosteres were evaluated.
The principal finding to emerge was that this region was an important determinant of the potency and kinetics of the activity of 1 analogues in tumor cells; the analogues exhibited varying ability to target the mitochondrion and elicit cell death. as a coupling reagent to form the amide bonds (Scheme 1). At completion of both reactions water was added to precipitate the products, which were isolated by filtration. The hydroxamic acid 1-HA was also synthesised from 1 using EDCI coupling (Scheme 1). [16] In the first step 1 was reacted with O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine to yield 2, a tetrahydropyranyl ether-protected intermediate of 1-HA. [17] Deprotection of 2 was achieved using hydrochloric acid in methanol, yielding 1-HA as a precipitate that was isolated by filtration and purified by trituration with methanol/water (50:50), followed by acetone.
The key intermediate in the synthesis of 1-SA and 1-OT was the bromourea 7, which was prepared using an adaptation of the procedure of Miwa et al. (Scheme 2) . [18] 15-Bromopentadecan-1-ol (3) was refluxed with potassium phthalimide to produce the intermediate 4 that was hydrolysed by refluxing with hydrazine to generate the primary amine
5.
The alcohol group in 5 was converted to a bromide using concentrated hydrobromic acid, yielding 6 as the hydrobromide salt that was purified by recrystallisation in acetone. The bromourea 7 was obtained by reacting 6 with 4-chloro, 3-(trifluoromethyl)phenylisocyanate in the presence of triethylamine, which served as a base to generate the free amine from the hydrobromide salt of 6. The sulfonic acid derivative 1-SA was prepared by refluxing bromourea 7 with sodium sulfite in aqueous ethanol for three days. The oxo-thiadiazole 1-OT was obtained by reacting 7 with sodium cyanide in DMSO and the resultant nitrile 8 was then treated with aqueous hydroxylamine solution to generate the amidoxime 9. Subsequently, 9 was reacted with 1,1′-thiocarbonyldiimidazole in acetonitrile to form the oxo-thiadiazole ring and yield 1-OT. [19] Impaired ATP production by analogues of 1 in breast cancer cells. Treatment of triple-negative MDA-MB-231 breast cancer cells with 1-OT and 1-SA (10 µM, 24 h) decreased ATP production to 33±4% (P<0.001) and 69±8% (P<0.05) of control, respectively.
In comparison, 1 decreased ATP production to 72±14% of control (P<0.05; Figure 1A ). Longer term treatment for 48 h produced more pronounced effects. Thus, 1-OT strongly decreased ATP production to 5±1% of control (P<0.001), while the activities of 1 and 1-SA were also greater ( Figure 1A) . Interestingly, the hydroxamic acid derivative 1-HA was highly active after 48 h of treatment despite its low activity at 24 h, while 1-A and 1-MA exerted minimal effects on ATP production even after 48 h of treatment. Different from DMSO-treated control: ***P<0.001, **P<0.01, *P<0.05.
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To corroborate the effects on ATP production, the impact of the 1 analogues on cell and suggesting that extensive cell deletion occurred rapidly with that analogue. Different from DMSO-treated control: *P<0.001, **P<0.01, *P<0.05.
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Aryl urea analogues target the mitochondrial membrane in MDA-MB-231 cells. 1 has been found previously to target the mitochondrion in MDA-MB-231 cells. [15] We assessed whether the present carboxylate-modified aryl-urea fatty acids also effected mitochondrial disruption using the membrane-permeable redox-active cationic dye JC- 
14

DISCUSSION
The development of well-tolerated anti-cancer agents with novel mechanisms of action could provide valuable options in the treatment of cancer patients. The long-chain fatty acid derivative 1 was recently identified as the first in a new class of potential anti-cancer agents with activity against MDA-MB-231 breast cancer cells. [19] The present study assessed the importance of the carboxylic acid group in the activity of The activity of 1-OT suggests that planar heterocyclic moieties may also be effective carboxylate isosteres. We attempted to prepare a tetrazole-containing bioisostere of 1 but were unable to synthesise this compound from bromourea 7 using established approaches.
Interestingly, the hydroxamic acid analogue 1-HA displayed different kinetics to 1, 1-SA and 1-OT, and required 48 h to produce extensive loss of cell viability. Unlike the other active agents evaluated in this study, 1-HA did not disrupt the mitochondrial membrane potential and appeared to activate necrotic death in a delayed fashion, rather than by the rapid activation of apoptosis produced by other analogues. Our ongoing studies to identify the cellular target(s) of 1 analogues may eventually assist with a more complete interpretation of the present findings.
In cancer cells the mitochondrion could contain novel drug targets because it is structurally and functionally different from the organelle in normal cells. [1] Whereas oxidative phosphorylation is the primary pathway by which ATP is generated in normal cells, aerobic glycolysis is more important in highly aggressive tumors cells (the Warburg effect). [20] Instead, the cancer cell mitochondrion is involved in the increased production of the macromolecules that are necessary for tumor cell replication. [1] The mitochondrion is also a critical regulator of apoptotic cell death and in cancer cells these pathways are frequently less responsive to cytotoxic agents. Thus, the development of novel agents that selectively damage the mitochondrion in tumor cells could lead to the development of new therapeutic strategies. 
EXPERIMENTAL SECTION
Chemistry.
General: All reagents and anhydrous solvents were purchased from Sigma Aldrich (Castle Hill, NSW, Australia). Dry Column Vacuum Chromatography was used to purify reaction products on silica gel with gradient elutions. TLC was performed on silica gel 60 F254 plates.
Melting points were measured on a Stuart SMP10 melting point apparatus. 1 
16-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]hexadecanamide (1-A):
Preparation of 16-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-N-(tetrahydro-2H-pyran-2-yloxy)hexadecanamide (2)
.
Preparation of 2-(15-hydroxypentadecyl)-1H-isoindole-1,3(2H)-dione (4)
. 15-bromo-1-pentadecanol (3, 3.000 g, 9.77 mmol) and potassium phthalimide (2.352 g, 12.70 mmol) were dissolved in anhydrous DMF (50 mL) under a nitrogen atmosphere. The solution was refluxed for 18 h and cooled to room temperature. The resulting mixture was filtered and the filter bed was washed with diethyl ether (50 mL). The filtrate was washed with distilled water (3×200 mL) and brine (2×100 mL), and then concentrated under reduced pressure. 
Preparation of 15-aminopentadecan-1-ol (5).
To a solution of 4 (2.230 g, 5.97 mmol) in anhydrous tetrahydrofuran (THF, 70 mL) under a nitrogen atmosphere was added hydrazine monohydrate (7 mL, 95 mmol). The resulting mixture was refluxed for 18 h and cooled to room temperature. The solvent and the excess of hydrazine were removed under reduced pressure.
The crude product was extracted with dichloromethane (200 mL) and aqueous sodium hydroxide (0.5M, 200 mL). The organic layer was separated and washed with aqueous sodium hydroxide (1M, 100 mL) and distilled water (2×100 mL), and then concentrated in vacuo, yielding 5 as an off-white solid (1.410 g, 96%). Mp = 58-60C. 1 
Preparation of 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-(15-cyanopentadecyl)urea (8).
To a solution of 7 (0.300 g, 0.569 mmol) in DMSO (20 mL) was added sodium cyanide (0.084 g, 1.71 mmol) at 40C. The resulting mixture was stirred for 18 h, and then cooled to room temperature. The resulting mixture was diluted with water (50 mL) and extracted with chloroform (3×100 mL). The organic layer was separated, washed with distilled water (2×100 mL) and brine (100 mL), and then concentrated in vacuo. The off-white solid was triturated twice with water, followed by diethyl ether and dried under vacuum to yield 8 as a white solid (0.218 g, 81% 
